Sickle Cell Safety Profile

Established Safety Profile in Children and Adults With Sickle Cell Disease Demonstrated
Over 5 Years1,2

  • Patients titrated ≥30 MG/KG/DAY Demonstrated A Continued Reduction in Body Iron Burden Without an Increase in Adverse Events or Evidence of Renal Dysfunction1
  • No Negative Impact on Growth or Sexual Development in Pediatric Patients3
  • No Progressive Increase in Mean Serum Creatinine Over 5 Years of Study2

Low discontinuation rates due to treatment-related
adverse events3:

EXJADE Low Discontinuation Rates

Safety details from the extension study

  • EXJADE had a favorable safety profile and appeared to be well tolerated3
  • The adverse event profile was similar to the core study and other previous registration trials3
  • Many of the adverse events reflected the underlying health condition (e.g., sickle cell anemia with crisis, or pyrexia, or infections) and were not treatment related3
  • Among the most frequent drug-related adverse events were those known to be inherent to iron chelators, including3:
    • Nausea
    • Diarrhea
    • Vomiting
    • Abdominal pain

SAFETY PROFILE ACROSS ANEMIAS

Learn more

EXJADE DOSING OPTIONS

Titrate from the recommended starting dose of 20 mg/kg/day based on individual patient's response and therapeutic goals. Please check the Prescribing Information for your region for details.

Learn more